HHS has sent drug for Ebola clinical trial

The U.S. Department of Health and Human Services (HHS) has sent a drug candidate to the U.S. Food and Drug Administration (FDA) for review as part of an Ebola clinical trial. This marks a significant step in the development of new treatments for the deadly virus. The drug, developed by HHS scientists, targets the Ebola virus and has shown promise in preclinical studies. The clinical trial will evaluate the drug's safety and efficacy in humans. If successful, it could offer a new therapeutic option for patients infected with Ebola, a disease that has caused numerous outbreaks with high mortality rates. The development process involved extensive research and testing by HHS, highlighting the government's commitment to combating infectious diseases.